MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the company will be participating in one-on-one meetings and a fireside chat presentation with investors at the 2025 BTIG Virtual Biotech Conference taking place from July 29-30, 2025. About Veru Inc.Veru is a late clinical stage biopharmaceutical company focused o ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic steatosis (fatty liver disease).The study, conducted at the Atlanta VA Medical Center, will ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic steatosis (fatty liver disease). The study, conducted at the Atlanta VA Medical Center, will ...

The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ETCORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2025 financial results after the market close on Wedne ...

Group 1 - SciSparc Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 per share for 10 consecutive business days [1][2] - The compliance determination by Nasdaq indicates that the prior bid price deficiency matter is now closed [2] - SciSparc is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [3] Group 2 - The company is led by an experienced team of senior executives and scientists, emphasizing its expertise in cannabinoid pharmaceuticals [3] - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com Marketplace [3]

Core Insights - Reunion Neuroscience Inc. announced the publication of Phase 1 study results for RE104, highlighting its favorable safety profile and short duration psychoactive experience [1][3] - The company is currently conducting the RECONNECT Phase 2 trial for RE104 in postpartum depression, with topline results expected in Q3 2025 [1][2] Group 1: Phase 1 Study Findings - The Phase 1 study involved administering a single subcutaneous dose of RE104 ranging from 5mg to 40mg to healthy adult volunteers, with psychoactive effects lasting 3-4 hours for doses above 5mg [2][6] - RE104 demonstrated a favorable safety and tolerability profile, with no serious adverse events reported, and treatment-emergent adverse events were mostly mild to moderate [3][6] - The active metabolite 4-OH-DiPT appeared rapidly in plasma, correlating with clinical assessments of drug effect [3][6] Group 2: Future Trials and Indications - Reunion Neuroscience plans to initiate the REKINDLE Phase 2 trial for adjustment disorder in Q3 2025, following the RECONNECT trial [5][7] - The company is also conducting a clinical lactation study to assess the elimination of RE104 and its metabolites in breastfeeding mothers, with final data expected in the second half of 2025 [4][5] Group 3: Company Overview - Reunion Neuroscience is focused on developing next-generation psychedelic-inspired therapeutic solutions for mental health disorders, having transitioned to a private company in 2023 and completed Series A financing in 2024 [8] - The lead product candidate, RE104, is designed to provide a shorter duration psychedelic experience compared to traditional psychedelics like psilocybin, while maintaining a similar safety profile [6][8]

GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc. Effective July 15th, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated b ...

PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio’s presentation ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Belite Bio (BLTE) is a clinical stage biopharmaceutical drug development company which focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases. The Zacks Consensus Estimate for its current year earnings has been revised 59.1% downward over the last 60 days.3D Systems (DD ...

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH) , a passively managed exchange traded fund launched on 12/20/2011.Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.Sector ETFs are also funds of convenience, offering many ways to gai ...